Find disease awareness content and relevant supporting materials

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Epclusa (sofosbuvir + velpatasvir), from Gilead Sciences in chronic hepatitis C virus (HCV) infection.

The FDA has approved supplemental application for Harvoni (ledipasvir and sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV)...

Areas covered: Available data on epidemiology, type, and possible risk factors for nephrotoxicity of sofosbuvir-containing treatment are reviewed. Related articles were collected by searching Scopus, Pubmed, and Science direct.

The FDA has approved Harvoni (ledipasvir + sofosbuvir) for use in patients with hepatitis C virus (HCV) infection co-infected with...

Gilead Sciences announced that the European Commission has granted marketing authorization for Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily...

The FDA has approved supplemental applications for Sovaldi (sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV) in children...

The CHMP has given an opinion on the use of a fixed-dose combination of ledipasvir and sofosbuvir from Gilead Sciences...

Bristol-Myers Squibb announced that the FDA has accepted for filing and review three supplemental New Drug Applications (sNDAs) for Daklinza...

Bristol-Myers Squibb Company (BMS) announced that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved on 24 July 2015...

Gilead Sciences has submitted a New Drug Application (NDA) to the FDA for once-daily fixed-dose combination of Sovaldi + GS...